- Home
- CKPT vs KTF Comparison
CKPT vs KTF Comparison
Compare CKPT & KTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- KTF
- Stock Information
- Founded
- CKPT 2014
- KTF 1988
- Country
- CKPT United States
- KTF United States
- Employees
- CKPT N/A
- KTF N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- KTF Finance Companies
- Sector
- CKPT Health Care
- KTF Finance
- Exchange
- CKPT Nasdaq
- KTF Nasdaq
- Market Cap
- CKPT 335.9M
- KTF 350.7M
- IPO Year
- CKPT 2017
- KTF N/A
- Fundamental
- Price
- CKPT $4.04
- KTF $8.96
- Analyst Decision
- CKPT Buy
- KTF
- Analyst Count
- CKPT 3
- KTF 0
- Target Price
- CKPT $4.33
- KTF N/A
- AVG Volume (30 Days)
- CKPT 1.7M
- KTF 103.3K
- Earning Date
- CKPT 05-09-2025
- KTF 01-01-0001
- Dividend Yield
- CKPT N/A
- KTF 3.54%
- EPS Growth
- CKPT N/A
- KTF N/A
- EPS
- CKPT N/A
- KTF 0.39
- Revenue
- CKPT $41,000.00
- KTF N/A
- Revenue This Year
- CKPT $102,182.93
- KTF N/A
- Revenue Next Year
- CKPT $351.71
- KTF N/A
- P/E Ratio
- CKPT N/A
- KTF $23.10
- Revenue Growth
- CKPT N/A
- KTF N/A
- 52 Week Low
- CKPT $1.38
- KTF $7.40
- 52 Week High
- CKPT $4.50
- KTF $9.12
- Technical
- Relative Strength Index (RSI)
- CKPT 63.60
- KTF 33.80
- Support Level
- CKPT $3.94
- KTF $8.93
- Resistance Level
- CKPT $4.06
- KTF $9.03
- Average True Range (ATR)
- CKPT 0.05
- KTF 0.13
- MACD
- CKPT -0.03
- KTF -0.02
- Stochastic Oscillator
- CKPT 83.33
- KTF 28.00
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.